Treatment of Lateral Knee Pain Using Soft Tissue Mobilization in Four Female Triathletes

od Winslow, John
Izdano 2014

Rehabilitation of a Young Athlete With Extension-Based Low Back Pain Addressing Motor-Control Impairments and Central Sensitization

od Winslow, John J., Jackson, Mark, Getzin, Andrew, Costello, Michael
Izdano u J Athl Train (2018)

Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanis...

od DeFazio-Eli, Lisa, Strommen, Kristi, Dao-Pick, Trang, Parry, Gordon, Goodman, Laurie, Winslow, John
Izdano 2011

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant

od Growdon, Whitfield B., Groeneweg, Jolijn, Byron, Virginia, DiGloria, Celeste, Borger, Darrell R., Tambouret, Rosemary, Foster, Rosemary, Chenna, Ahmed, Sperinde, Jeff, Winslow, John, Rueda, Bo R.
Izdano u Gynecol Oncol (2015)

INCREASED EXPRESSION OF HER2, HER3 and HER2:HER3 HETERODIMERS IN HPV-POSITIVE HNSCC USING A NOVEL PROXIMITY-BASED ASSAY: IMPLICATIONS FOR TARGETED THERAPIES

od Pollock, Netanya I., Wang, Lin, Wallweber, Gerald, Gooding, William E, Huang, Weidong, Chenna, Ahmed, Winslow, John, Sen, Malabika, DeGrave, Kara, Li, Hua, Zeng, Y, Grandis, Jennifer R.
Izdano u Clin Cancer Res (2015)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

od Toi, Masakazu, Sperinde, Jeff, Huang, Weidong, Saji, Shigehira, Winslow, John, Jin, Xueguang, Tan, Yuping, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Aogi, Kenjiro, Morita, Satoshi, Petropoulos, Christos, Bates, Michael
Izdano 2010

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

od Bauman, Julie E., Ohr, James, Gooding, William E., Ferris, Robert L., Duvvuri, Umamaheswar, Kim, Seungwon, Johnson, Jonas T., Soloff, Adam C., Wallweber, Gerald, Winslow, John, Gaither-Davis, Autumn, Grandis, Jennifer R., Stabile, Laura P.
Izdano u Cancers (Basel) (2020)

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

od Chumsri, Saranya, Sperinde, Jeff, Liu, Heshan, Gligorov, Joseph, Spano, Jean-Philippe, Antoine, Martine, Aspitia, Alvaro Moreno, Tan, Winston, Winslow, John, Petropoulos, Christos J, Chenna, Ahmed, Bates, Michael, Weidler, Jodi Marie, Huang, Weidong, Dueck, Amylou, Perez, Edith A.
Izdano u Clin Cancer Res (2018)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

od Duchnowska, Renata, Sperinde, Jeff, Czartoryska-Arłukowicz, Bogumiła, Myśliwiec, Paulina, Winslow, John, Radecka, Barbara, Petropoulos, Christos, Demlova, Regina, Orlikowska, Marlena, Kowalczyk, Anna, Lang, Istvan, Ziółkowska, Barbara, Dębska-Szmich, Sylwia, Merdalska, Monika, Grela-Wojewoda, Aleksandra, Żawrocki, Anton, Biernat, Wojciech, Huang, Weidong, Jassem, Jacek
Izdano u Oncotarget (2017)

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases

od Duchnowska, Renata, Sperinde, Jeff, Chenna, Ahmed, Huang, Weidong, Weidler, Jodi M., Winslow, John, Haddad, Mojgan, Paquet, Agnes, Lie, Yolanda, Trojanowski, Tomasz, Mandat, Tomasz, Kowalczyk, Anna, Czartoryska-Arłukowicz, Bogumiła, Radecka, Barbara, Jarosz, Bożena, Staszkiewicz, Rafal, Kalinka-Warzocha, Ewa, Chudzik, Małgorzata, Biernat, Wojciech, Jassem, Jacek
Izdano u Neuro Oncol (2015)

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

od Ghosh, Ritwik, Narasanna, Archana, Wang, Shizhen Emily, Liu, Shuying, Chakrabarty, Anindita, Balko, Justin M., González-Angulo, Ana María, Mills, Gordon B., Penuel, Elicia, Winslow, John, Sperinde, Jeff, Dua, Rajiv, Pidaparthi, Sailaja, Mukherjee, Ali, Leitzel, Kim, Kostler, Wolfgang J., Lipton, Allan, Bates, Michael, Arteaga, Carlos L.
Izdano 2011

Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark(®)) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breas...

od Larson, Jeffrey S., Goodman, Laurie J., Tan, Yuping, Defazio-Eli, Lisa, Paquet, Agnes C., Cook, Jennifer W., Rivera, Amber, Frankson, Kristi, Bose, Jolly, Chen, Lili, Cheung, Judy, Shi, Yining, Irwin, Sarah, Kiss, Linda D. B., Huang, Weidong, Utter, Shannon, Sherwood, Thomas, Bates, Michael, Weidler, Jodi, Parry, Gordon, Winslow, John, Petropoulos, Christos J., Whitcomb, Jeannette M.
Izdano 2010

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

od Lipton, Allan, Goodman, Laurie, Leitzel, Kim, Cook, Jennifer, Sperinde, Jeff, Haddad, Mojgan, Köstler, Wolfgang J., Huang, Weidong, Weidler, Jodi M., Ali, Suhail, Newton, Alicia, Fuchs, Eva-Marie, Paquet, Agnes, Singer, Christian F., Horvat, Reinhard, Jin, Xueguang, Banerjee, Joyee, Mukherjee, Ali, Tan, Yuping, Shi, Yining, Chenna, Ahmed, Larson, Jeff, Lie, Yolanda, Sherwood, Thomas, Petropoulos, Christos J., Williams, Stephen, Winslow, John, Parry, Gordon, Bates, Michael
Izdano 2013

p95HER2–T cell bispecific antibody for breast cancer treatment

od Ruiz, Irene Rius, Vicario, Rocio, Morancho, Beatriz, Morales, Cristina Bernadó, Arenas, Enrique J., Herter, Sylvia, Freimoser-Grundschober, Anne, Somandin, Jitka, Sam, Johannes, Ast, Oliver, Barriocanal, Águeda Martinez, Luque, Antonio, Escorihuela, Marta, Varela, Ismael, Cuartas, Isabel, Nuciforo, Paolo, Fasani, Roberta, Peg, Vicente, Rubio, Isabel, Cortés, Javier, Serra, Violeta, Escriva-de-Romani, Santiago, Sperinde, Jeff, Chenna, Ahmed, Huang, Weidong, Winslow, John, Albanell, Joan, Seoane, Joan, Scaltriti, Maurizio, Baselga, Jose, Tabernero, Josep, Umana, Pablo, Bacac, Marina, Saura, Cristina, Klein, Christian, Arribas, Joaquín
Izdano u Sci Transl Med (2018)